New diabetes injection aims to control blood sugar without weight gain
NCT ID NCT06881264
Summary
This study tested a new injectable drug called HR17031 against a standard insulin (glargine) in Chinese adults whose type 2 diabetes was not well controlled with oral medications. The main goal was to see if HR17031 could lower long-term blood sugar levels (HbA1c) as effectively as insulin over 26 and 52 weeks, while also looking at effects on body weight and safety. Participants were randomly assigned to receive one of the two treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETIC DRUGS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.